Food and Drug Administration (FDA) issued new label warnings for Ozempic, indicating that it can increase the risk of intestinal blockages
Pediatric Obesity: Should We Prescribe GLP-1 Agonists for Adolescents
Research in rodents has shown that mimics like semaglutide alter the reward pathways in the brain, potentially reducing addictions to food, drugs, and tobacco
Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial
04, 2025 (GLOBE NEWSWIRE) -- Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
Focus on resistance training to preserve muscle during weight loss